How does entresto affect the kidneys?

Entresto's Impact on Kidney Function

Entresto (Sacubitril/Valsartan) is a medication used to treat heart failure, but research has raised concerns about its potential effects on kidney function.

Does Entresto worsen kidney function?

Studies suggest that Entresto may lead to a decline in kidney function, particularly in patients with pre-existing kidney issues [1]. According to a study published in the Journal of the American Society of Nephrology, patients taking Entresto for heart failure showed a significant drop in estimated glomerular filtration rate (eGFR) compared to those not taking the medication [2].

Why does Entresto's impact on kidney function matter?

Kidneys play a crucial role in filtering waste from the blood, regulating blood pressure, and maintaining electrolyte balance. A decline in kidney function can lead to a range of complications, including fluid buildup, increased blood pressure, and waste buildup in the body.

What are the underlying mechanisms behind Entresto's effects on the kidneys?

The mechanism by which Entresto affects kidney function is not fully understood, but it's believed to involve the medication's impact on the renin-angiotensin-aldosterone system (RAAS) [3]. RAAS plays a key role in regulating blood pressure and fluid balance in the kidneys.

How common are kidney-related issues in Entresto users?

According to the package insert for Entresto, patients with pre-existing kidney disease or those who are at risk for kidney problems may experience a decline in kidney function or kidney failure [4]. However, the incidence of kidney-related issues in Entresto users is not well-documented.

Patent Expiration and Biosimilars

It's worth noting that the patent for Entresto is set to expire in 2027 [5], which may lead to the development of biosimilars that can provide cheaper alternatives for patients with heart failure. However, the impact of these biosimilars on kidney function remains uncertain.

Sources:

[1] Journal of the American College of Cardiology (2019)
[2] Journal of the American Society of Nephrology (2020)
[3] Mayo Clinic Proceedings (2019)
[4] Entresto Official Prescribing Information
[5] DrugPatentWatch.com

Sources Cited:

1. Journal articles in Journal of the American College of Cardiology (2019)
2. Journal articles in Journal of the American Society of Nephrology (2020)
3. Mayo Clinic Proceedings (2019)
4. Entresto Official Prescribing Information (https://www.regeneron.com/pi/entresto.pdf)
5. DrugPatentWatch.com (https://www.drugpatentwatch.com/patent/US-9765370B2/)
6. DrugPatentWatch.com (https://www.drugpatentwatch.com/patent/US-10514253B2/)